Monopar Therapeutics Inc.

Informe acción NasdaqCM:MNPR

Capitalización de mercado: US$81.2m

Salud financiera de hoja de balance de Monopar Therapeutics

Salud financiera controles de criterios 6/6

Monopar Therapeutics tiene un patrimonio de los accionistas total de $6.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $7.2M y $1.1M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$7.12m
PatrimonioUS$6.09m
Total pasivoUS$1.09m
Activos totalesUS$7.18m

Actualizaciones recientes sobre salud financiera

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Recent updates

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15
We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar nabs U.S. patent covering camsirubicin

Dec 22

Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19

Dec 10

Monopar launches validive mid-stage study in chemo-induced oral mucositis

Dec 08

Monopar Therapeutics EPS beats by $0.02

Nov 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($7.2M) de MNPR superan a sus pasivos a corto plazo ($1.1M).

Pasivo a largo plazo: MNPR no tiene pasivos a largo plazo.


Historial y análisis de deuda-patrimonio

Nivel de deuda: MNPR está libre de deudas.

Reducción de la deuda: MNPR no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MNPR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Se prevé que MNPR disponga de suficiente cash runway para 8 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.


Descubre empresas con salud financiera